Search

Your search keyword '"Paz Ares L"' showing total 1,903 results
Start Over Author "Paz Ares L"

Refine your results

1,903 results on '"Paz Ares L"'

151. 1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer

Author

Passiglia, F., primary, Tabbò, F., additional, Righi, L., additional, Bironzo, P., additional, Reale, M.L., additional, Listi, A., additional, Sini, C., additional, Vallone, S., additional, Arizio, F., additional, Secen, N.M., additional, Paz-Ares, L., additional, Felip, E., additional, Araújo, A., additional, Linardou, H., additional, Mohorcic, K., additional, Mazilu, L., additional, Szmytke, E., additional, Comanescu, A., additional, Scagliotti, G., additional, and Novello, S., additional

Published
2021
Full Text
View/download PDF

152. LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

Author

Paz-Ares, L., primary, Chen, Y., additional, Reinmuth, N., additional, Hotta, K., additional, Trukhin, D., additional, Statsenko, G., additional, Hochmair, M.J., additional, Ozguroglu, M., additional, Ji, J.H., additional, Voitko, O., additional, Poltoratskiy, A., additional, Verderame, F., additional, Havel, L., additional, Bondarenko, I., additional, Losonczy, G., additional, Conev, N.V., additional, Broadhurst, H.L., additional, Dalvi, T., additional, Jiang, H., additional, and Goldman, J.W., additional

Published
2021
Full Text
View/download PDF

155. Corrigendum to 'Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)' [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978] (Critical Reviews in Oncology / Hematology (2020) 151, (S1040842820301165), (10.1016/j.critrevonc.2020.102978))

Author

Rolfo C., Cardona A. F., Cristofanilli M., Paz-Ares L., Diaz Mochon J. J., Duran I., Raez L. E., Russo A., Lorente J. A., Malapelle U., Gil-Bazo I., Jantus-Lewintre E., Pauwels P., Mok T., Serrano M. J., Rolfo, C., Cardona, A. F., Cristofanilli, M., Paz-Ares, L., Diaz Mochon, J. J., Duran, I., Raez, L. E., Russo, A., Lorente, J. A., Malapelle, U., Gil-Bazo, I., Jantus-Lewintre, E., Pauwels, P., Mok, T., and Serrano, M. J.

Abstract

The authors wish to change the affiliation details of Eloisa Jantus-Lewintre as follows: 20Molecular Oncology Laboratory, General University Hospital of Valencia Research Foundation; Department of Biotechnology, Univeristat Politècnica de València; CIBERONC, Spain. The authors take sole responsibility for this notice and would like to apologize to readers and editors of CROH for any inconvenience that it may have caused in the publication process of the article.

Published
2020

157. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Author

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E. F., Syrigos, K., Stahel, R., Felip, E., Peters, S., Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, OʼByrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinò, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, and Westeel, Virginie

Published
2014
Full Text
View/download PDF

159. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

Author

Majem, M, Cobo, M, Isla, D, Marquez-Medina, D, Rodriguez-Abreu, D, Casal-Rubio, J, Moran-Bueno, T, Bernabe-Caro, R, Perez-Parente, D, Ruiz-Gracia, P, Arroyo, MM, and Paz-Ares, L

Subjects
efficacy, immunotherapy, network meta-analysis, first-line treatment, PD-(L)1 inhibitors, non-small cell lung cancer
Abstract

Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (>= 50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HRpooled = 0.69, 95% CI: 0.52-0.90, p = 0.007), overall survival (OS: HRpooled = 0.69, 95% CI: 0.61-0.78; p < 0.001) and overall response rate (ORR) (Risk ratio (RR)(pooled) = 1.354, 95% CI: 1.04-1.762, p = 0.024). In the assessment of relative efficacy for PFS through indirect comparisons, pembrolizumab (results from KEYNOTE-024) ranked highest followed by cemiplimab and atezolizumab, with statistical significance determined for some of the drugs. In terms of OS, cemiplimab ranked highest followed by atezolizumab and pembrolizumab, although non-significant OS was determined for these drugs. In conclusion, PD-(L)1 inhibitor monotherapy improves efficacy outcomes in the first line setting of advanced NSCLC patients with high PD-L1 expression. Evaluations with longer follow up are still needed to determine the superiority of any specific drug.

Published
2021

161. A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)

Author

Reck, M., Mileham, K., Paz-Ares, L., Surmont, V., Felip, E., Vinolas, N., Bessudo, A., Clump, D., Decoster, L., Estival, A., Sebastian, M., Chen, H., Chisamore, M., Wagner, V. J., Wagner, A., Smit, E. F. F., Clinical sciences, Medical Oncology, and Laboratory of Molecular and Medical Oncology

Abstract

Background: Nivolumab or pembrolizumab is the standard second-line treatment for patients (pts) with advanced NSCLC. Anlotinib is an oral VEGFR, FGFR, PDGFR and c-Kit tyrosine kinase inhibitor. The interaction between tumor immune microenvironment and angiogenesis has been well established.This study was designed to assess the benefit and optimal time of nivolumab or pembrolizumab plus anlotinib in previously treated advanced NSCLC. Methods: This is a prospective observational study. Pts with advanced NSCLC who had previous progression after platinum-based chemotherapy were eligible. For NSCLC with EGFR variations pts who had disease progression with prior EGFR TKI therapies and chemotherapy were also eligible. Nivolumab on day 1 (3 mg/kg) every 2 weeks or pembrolizumab on day 1 (200 mg) every 3 weeks for up to 8 weeks, for pts who have no symptomatic deterioration and can benefit from the treatment, then followed by the former therapy plus anlotinib maintenance until progression or unacceptable toxic effects. Anlotinib was given orally 12mg for 2 weeks of a 21-day cycle (days 1-14). The primary outcome was ORR. The secondary outcomes were DCR, PFS, OS and safety. Results: From Mar-2019 to Apr-2021, a total of 19 pts were enrolled. Most were male (84.2%), adenocarcinoma histology (68.4%) and most were treated as second-line treatment (57.9%). 4 had baseline brain metastases. For 8 weeks’ treatment of nivolumab or pembrolizumab monotherapy, 5 pts achieved PR, 8 pts achieved SD and 6 pts had PD; ORR was 26.3%, DCR was 73.7%. During the anti-PD-1 therapy plus anlotinib, 1 pt achieved CR, 12 pts achieved PR (4 of them were PD during monotherapy), 4 pts achieved SD. ORR was 68.4%, DCR was 89.5%. Median PFS was 13.1 months (95% CI 8.6 to14.9). Grade 3 TRAE occurred in 26% pts. 2 pts with squamous cell carcinoma died due to pulmonary embolism and respiratory tract hemorrhage. The most common TRAE were fatigue, hypothyroidism and rash. Conclusions: Anti-PD-1 therapy plus anlotinib has shown promising anti-tumor efficacy compared to the previous anti-PD-1 monotherapy studies for pts with previously treated advanced NSCLC, and with a tolerable safety profile. We may focus on exploring the optimal time and advantage group of this combination in future studies.

Published
2021

164. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

Author

Faivre-Finn, C., Vicente, D., Kurata, T., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Spigel, D. R., Garassino, M. C., Reck, M., Senan, S., Naidoo, J., Rimner, A., Wu, Y-L., Gray, J. E., Ozguroglu, M., Lee, K. H., Newton, M., Wang, L., Thiyagarajah, P., Antonia, S. J., Radiation Oncology, and CCA - Cancer Treatment and quality of life

Published
2020
Full Text
View/download PDF

169. 509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

Author

Ahn, M-J., Lisberg, A.E., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo Dols, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Sands, J., Hall, R., Zhang, Y., Zebger-Gong, H., Uema, D., and Okamoto, I.

Published
2023
Full Text
View/download PDF

172. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

Author

Ahn, M-J., Lisberg, A., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo Dols, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Sands, J., Hall, R., Zhang, Y., Zebger-Gong, H., Uema, D., and Okamoto, I.

Published
2023
Full Text
View/download PDF

173. LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study

Author

Girard, N., Park, K., Tang, K., Cho, B.C., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J.W., Sabari, J.K., Sanborn, R.E., Mansfield, A.S., Hung, J-Y., Popat, S., Dias, J., Bhattacharya, A., Agrawal, T., Shreeve, M., Knoblauch, R.E., and Zhou, C.

Published
2023
Full Text
View/download PDF

174. LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6

Author

Garassino, M.C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L.S., Mansy, T., Cortinovis, D.L., Migliorino, M.R., Delmonte, A., García Sanchez, J., Chara Velarde, L.E., Bernabe Caro, R., Paz-Ares, L., Chander, P., Diaz Perez, I., Foroutanpour, K., and Faivre-Finn, C.

Published
2023
Full Text
View/download PDF

175. 151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

Author

Smit, E.F., Felip, E., Uprety, D., Nagasaka, M., Nakagawa, K., Paz-Ares, L., Pacheco, J., Li, B.T., Planchard, D., Baik, C.S., Goto, Y., Murakami, H., Pereira, K.M.C., Taguchi, A., Kogo, M., Kuwahara, Y., Zou, M., Feng, W., Tsuchihashi, Z., and Jänne, P.A.

Published
2023
Full Text
View/download PDF

176. 1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)

Author

Felip, E., Krebs, M.G., Carcereny, E., Smeland, K.B., Arriola, E., Llacer Perez, C., Thompson, J., Paz-Ares, L., Domine Gomez, M., Olivares, J.R., Vinolas Segarra, N., García-Campelo, M.R., Ortega Granados, A.L.O., Chisamore, M., Micklem, D., McCracken, N., Rayford, A., Oliva, C., Gorcea-Carson, C., and Spicer, J.

Published
2023
Full Text
View/download PDF

177. 1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01

Author

Brandão, M., Hiltermann, J.T.J.N., Wauters, E., Solomon, B.J., Castanon Alvarez, E., Felip, E., Gort, E.H., Izumi, H., Kim, D-W., Paz-Ares, L., Rohrberg, K.S., Steinbusch, L., Yoshida, T., Chen, H., Colebrook, S., Achour, I., Origuchi, M., Aroldi, F., and Cho, B.C.

Published
2023
Full Text
View/download PDF

180. 1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)

Author

Prat, A., Pascual, T., Juan, M., Paz-Ares, L., Felip, E., Garralda, E., Gonzalez-farre, B., Arance Fernandez, A.M., Martin-Liberal, J., López, A., Izarzugaza Peron, Y., Garcia-Corbacho, J., Saura Manich, C., Hierro, C., Sanfeliu Torres, E., Cejalvo, J.M., Salvador, F., Mesia Nin, R., Cervantes, A., and Tabernero, J.

Published
2023
Full Text
View/download PDF

183. 2246P Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study

Author

Solis, E. Segui, Torres, E. Sanfeliu, Gonzalez-Farre, B., Pascual, T., Brasó-Maristany, F., Galván, P., Farre, X. González, Salvador, F., Felip, E., Garralda, E., Paz-Ares, L., Juan, M., Nin, R. Mesia, Fernandez, A.M. Arance, Cervantes, A., Martin-Liberal, J., Javierre, G. Villacampa, Tabernero, J., and Prat, A.

Published
2023
Full Text
View/download PDF

184. 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types

Author

Solis, E. Segui, Pascual, T., Torres, E. Sanfeliu, Gonzalez-farre, B., Brasó-Maristany, F., Farre, X. González, Salvador, F., Felip, E., Garralda, E., Paz-Ares, L., Otero, M.J., Nin, R. Mesia, Fernandez, A.M. Arance, Cervantes, A., Martin-Liberal, J., Gavilá-Gregori, J., Parraga, K. Amillano, Racca, F.E., Tabernero, J., and Prat, A.

Published
2023
Full Text
View/download PDF

185. 1993P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results

Author

Casado, M.D. Isla, Arriola, E., García-Campelo, M.R., Tain, P. Diz, Blanco, C. Marti, Lopez-Brea Piqueras, M.M., Moreno Vega, A.L., Leon Mateos, L.A., Oramas Rodriguez, J.M., Calderon, V. Gutierrez, Majem, M., Hernandez, A. Sanchez, Aguado, C., Cabellos, R. Alvarez, Marti Ciriquian, J.L., Paul, A. Moreno, Firvida Perez, J.L., Mellén, Á. Callejo, Baez, L., and Paz-Ares, L.

Published
2023
Full Text
View/download PDF

189. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Author

Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchiy, P, Martin, C, Perol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, John, T, Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchiy, P, Martin, C, Perol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, and John, T

Abstract

BACKGROUND: To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. PATIENTS AND METHODS: Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. RESULTS: With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. CONCLUSIONS: With a 2-year minimum follow-up, nivolumab plus ipilimumab wi

Published
2021

191. Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial

Author

Spira, A., primary, Ardizzoni, A., additional, Barlesi, F., additional, Cho, B.C., additional, De Marchi, P., additional, Goto, Y., additional, Kowalski, D., additional, Lu, S., additional, Paz-Ares, L., additional, Spigel, D.R., additional, Thomas, M., additional, Turri, S., additional, Rodrik-Outmezguine, V., additional, Zhou, W., additional, Kreisl, T., additional, Yang, J.C.-H., additional, and Garon, E.B., additional

Published
2021
Full Text
View/download PDF

192. 98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

Author

Paz-Ares, L., primary, Ciuleanu, T-E., additional, Cobo, M., additional, Schenker, M., additional, Zurawski, B., additional, Menezes, J., additional, Richardet, E., additional, Bennouna, J., additional, Felip, E., additional, Juan-Vidal, O., additional, Alexandru, A., additional, Sakai, H., additional, Scherpereel, A., additional, Reck, M., additional, Lu, S., additional, John, T., additional, Meadows-Shropshire, S., additional, Balli, D., additional, Agrawal, S., additional, and Carbone, D.P., additional

Published
2021
Full Text
View/download PDF

193. 48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)

Author

Paz-Ares, L., primary, Owonikoko, T.K., additional, Johnson, M., additional, Govindan, R., additional, Izumi, H., additional, Lai, V., additional, Borghaei, H., additional, Boyer, M., additional, Boosman, R.J., additional, Hummel, H-D., additional, Blackhall, F., additional, Dowlati, A., additional, Zhang, Y., additional, Mukherjee, S., additional, Sable, B., additional, Pati, A., additional, Shetty, A., additional, Sadraei, N. Hashemi, additional, and Champiat, S., additional

Published
2021
Full Text
View/download PDF

194. 97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

Author

Robinson, A.G., primary, Vicente, D., additional, Tafreshi, A., additional, Parra, H. Soto, additional, Mazieres, J., additional, Cicin, I., additional, Medgyasszay, B., additional, Rodríguez-Cid, J., additional, Okamoto, I., additional, Lee, S., additional, Ramlau, R., additional, Vladimirov, V., additional, Cheng, Y., additional, Halmos, B., additional, Liu, C-C., additional, Schwarzenberger, P., additional, Piperdi, B., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

195. 50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

Author

Aix, S. Ponce, primary, Juan-Vidal, O., additional, Carcereny, E., additional, Trigo, J.M., additional, Provencio, M., additional, Greillier, L., additional, Navarro, A., additional, Bennouna, J., additional, Santoro, A., additional, Berardi, R., additional, Besse, B., additional, Gonzalez, H., additional, de Alvaro, J., additional, Parra-Palau, J.L., additional, Sánchez-Pérez, T., additional, Aronchik, I., additional, Filvaroff, E., additional, Lamba, M., additional, Nikolova, Z., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

196. P48.21 Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

Author

Zheng, Y., primary, Jin, D., additional, Guan, Y., additional, Özgüroğlu, M., additional, Trukhin, D., additional, Poltoratskiy, A., additional, Chen, Y., additional, Havel, L., additional, Hochmair, M., additional, Paz-Ares, L., additional, Jiang, H., additional, Armstrong, J., additional, Chen, C., additional, Liu, Y.H., additional, and Roskos, L., additional

Published
2021
Full Text
View/download PDF

200. OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

Author

Nakagawa, K., primary, Nagasaka, M., additional, Felip, E., additional, Pacheco, J., additional, Baik, C., additional, Goto, Y., additional, Saltos, A., additional, Li, B., additional, Udagawa, H., additional, Gadgeel, S., additional, Murakami, H., additional, Planchard, D., additional, Bazhenova, L., additional, Paz-Ares, L., additional, Perol, M., additional, Mazieres, J., additional, Barlesi, F., additional, Saxena, K., additional, Shiga, R., additional, Acharyya, S., additional, Cheng, Y., additional, Shahidi, J., additional, Jänne, P., additional, and Smit, E., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results